Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSC), which remain a potential source of relapse. Here we investigated the ability of HDAC inhibitors (HDACi) to target CML stem cells. Treatment with HDACi combined wi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zhang, Bin, Strauss, Adam C., Chu, Su, Li, Min, Ho, Yinwei, Shiang, Keh-Dong, Snyder, David S, Huettner, Claudia S., Shultz, Leonard, Holyoake, Tessa, Bhatia, Ravi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2873971/
https://ncbi.nlm.nih.gov/pubmed/20478526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2010.03.011
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak